NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aeromics

Aeromics

Private
New Haven, ConnecticutHealthcare & Life Scienceshttps://www.aeromics.com/

Last Round

Strategic

Nov 5, 2019

Total Funding Raised

$10.14M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Aeromics is a pharmaceuticals company that develops anti-edema therapies designed to treat patients affected by acute central nervous system edema.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

cerebral edema treatmentischemic stroke treatmentaquaporin-4 inhibitorAQP4 inhibitorfirst-in-class drugneurotherapeuticsstroke drugprodrugdrug developmentclinical-stage pharmapharmaceutical licensingaquaporinsLarge Hemispheric InfarctionLHI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aeromics Comparables

Compare Aeromics with similar companies based on industry and business-model similarity.

Aeromics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Remedy Pharmaceuticals
89%
Egret Therapeutics
78%
Simcere Pharmaceutical Group
76%

Aeromics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 5, 2019
VC RoundJun 19, 2018
Series AOct 1, 2017
SeedApr 6, 2016
GrantDec 7, 2009
Grant
Sep 15, 2008

Aeromics Investors

Notable investors and investment history

Aeromics investors
InvestorRounds
Connecticut InnovationsVC Round, Series A, Seed
NIH RADxGrant
Broadview VenturesVC Round, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 20, 2026

    Monthly visitors grew 33% MoM.

  • Jun 1, 2025

    Monthly visitors increased 72% MoM, reaching 1.4K.

Aeromics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aeromics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aeromics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Haven, Connecticut
Employee Range2
Year Founded2006
Last FundingNov 5, 2019

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.